STAT3 and hepatocellular carcinoma: It is worth noting that STAT3 is one of the targets of sorafenib, a generic kinase inhibitor approved for the treatment of unresectable HCC, and that the inhibition of STAT3 is essential for the sensitization of HCC cells to an agonistic DR5 antibody (LBY135) and for TRAIL-induced apoptosis in TRAIL-resistant HCC cells [308].